Advertisement
SYRE vs TRVI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Hold and TRVI is a StrongBuy.
SYRE's Stochastic Oscillator sits in overbought zone for 9 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SYRE moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.168) is normal, around the industry mean (3.051). P/E Ratio (-51.720) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for TRVI turns positive, indicating new upward trend
TRVI saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 74 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TRVI's RSI Indicator exited the oversold zone, 19 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for TRVI just turned positive on October 20, 2026. Looking at past instances where TRVI's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
Following a +2.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in 240 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
TRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for TRVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.142) is normal, around the industry mean (3.051). P/E Ratio (-39.600) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 26 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SYRE | TRVI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 26 | |
SMR RATING 1..100 | 96 | 95 | |
PRICE GROWTH RATING 1..100 | 35 | 60 | |
P/E GROWTH RATING 1..100 | 50 | 26 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (6) in the Pharmaceuticals Major industry is in the same range as TRVI (6). This means that SYRE’s stock grew similarly to TRVI’s over the last 12 months.
TRVI's Profit vs Risk Rating (26) in the Pharmaceuticals Major industry is significantly better than the same rating for SYRE (100). This means that TRVI’s stock grew significantly faster than SYRE’s over the last 12 months.
TRVI's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as SYRE (96). This means that TRVI’s stock grew similarly to SYRE’s over the last 12 months.
SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as TRVI (60). This means that SYRE’s stock grew similarly to TRVI’s over the last 12 months.
TRVI's P/E Growth Rating (26) in the Pharmaceuticals Major industry is in the same range as SYRE (50). This means that TRVI’s stock grew similarly to SYRE’s over the last 12 months.
| SYRE | TRVI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| Advances ODDS (%) | 8 days ago 87% | 2 days ago 85% |
| Declines ODDS (%) | 3 days ago 87% | 10 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 86% |
| Aroon ODDS (%) | 3 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SYRE’s FA Score shows that 1 FA rating(s) are green while TRVI’s FA Score has 3 green FA rating(s).
- SYRE’s FA Score: 1 green, 4 red.
- TRVI’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SYRE’s TA Score shows that 6 TA indicator(s) are bullish while TRVI’s TA Score has 5 bullish TA indicator(s).
- SYRE’s TA Score: 6 bullish, 4 bearish.
- TRVI’s TA Score: 5 bullish, 3 bearish.
Price Growth
SYRE (@Biotechnology) experienced а +0.23% price change this week, while TRVI (@Biotechnology) price change was +3.82% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.31%. For the same industry, the average monthly price growth was -10.93%, and the average quarterly price growth was -16.13%.
Reported Earning Dates
SYRE is expected to report earnings on Mar 04, 2027.
TRVI is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-3.31% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
TRVI and
Correlation & Price change
A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with TSHA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then TSHA could also see price increases.
| Ticker / NAME | Correlation To TRVI | 1D Price Change % | ||
|---|---|---|---|---|
| TRVI | 100% | +1.69% | ||
| TSHA - TRVI | 46% Loosely correlated | +2.25% | ||
| KURA - TRVI | 43% Loosely correlated | +0.92% | ||
| PTGX - TRVI | 43% Loosely correlated | +0.62% | ||
| SYRE - TRVI | 43% Loosely correlated | +3.94% | ||
| PVLA - TRVI | 42% Loosely correlated | +4.51% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| COYY | 12.49 | 0.06 | +0.52% |
| GraniteShares YieldBOOST COIN ETF (COYY) | |||
| IWV | 428.45 | 1.46 | +0.34% |
| iShares Russell 3000 ETF (IWV) | |||
| TRND | 36.05 | 0.07 | +0.20% |
| Pacer Trendpilot Fund of Funds ETF (TRND) | |||
| DBND | 43.96 | -0.06 | -0.14% |
| DoubleLine Opportunistic Core Bond ETF (DBND) | |||
| DJIA | 22.36 | -0.14 | -0.62% |
| Global X Dow 30 Covered Call ETF (DJIA) | |||